Want to see SGMT full AI Analyst Report?
Top Page
Sagimet Biosciences, Inc. Class A
(NASDAQ:SGMT)
Select Model
Select Model
Rating:57Neutral
Price Target:
$10.00
▲(41.44% Upside)
Action:Reiterated
Date:08/11/26
The score is driven primarily by uneven fundamentals: a strong, low-debt balance sheet is offset by ongoing losses and material cash burn. Technicals are supportive with a clear uptrend, but overbought readings raise near-term volatility risk. Valuation is a headwind because the negative P/E reflects lack of profitability, while corporate updates (financing runway and Phase 3 plans) modestly improve the outlook.
Positive Factors
Low leverage and expanding asset base
Very low debt and materially expanded assets provide durable financial flexibility for a clinical-stage biotech. This capital structure reduces near-term liquidity stress, supports multi-year R&D plans and gives management optionality to fund registrational trials or partnerships without immediate cash-flow dependence.
Negative Factors
Sustained negative cash generation
Persistent negative operating and free cash flow is a durable headwind for a development-stage company. Ongoing cash burn necessitates external financing to progress registrational programs, increases dilution risk over time, and constrains flexibility if trial timelines or costs extend beyond current plans.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage and expanding asset base
Very low debt and materially expanded assets provide durable financial flexibility for a clinical-stage biotech. This capital structure reduces near-term liquidity stress, supports multi-year R&D plans and gives management optionality to fund registrational trials or partnerships without immediate cash-flow dependence.
Read all positive factors
Sagimet Biosciences, Inc. Class A (SGMT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$567.79M
Dividend YieldN/A
Average Volume (3M)1.31M
Price to Earnings (P/E)―
Beta (1Y)2.97
Revenue GrowthN/A
EPS Growth30.54%
CountryUS
Employees16
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.28
Shares Outstanding61,184,315
10 Day Avg. Volume983,121
30 Day Avg. Volume1,309,129
Financial Highlights & Ratios
PEG Ratio-0.42
Price to Book (P/B)1.72
Price to Sales (P/S)0.00
P/FCF Ratio-4.19
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$29.57Price Target Upside318.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.2
Revenue Forecast (FY)N/A
Sagimet Biosciences, Inc. Class A Business Overview & Revenue Model
Company Description
Sagimet Biosciences, Inc. (SGMT) is a clinical-stage biopharmaceutical company focused on developing small-molecule therapeutics that target fatty acid synthase (FASN) to treat metabolic and liver-related diseases. The company’s development effort...
How the Company Makes Money
null...
Sagimet Biosciences, Inc. Class A Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
72
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 2.00M | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 2.00M | 0.00 | 0.00 |
| EBITDA | -49.70M | -51.04M | -45.57M | -27.88M | -30.37M | -24.44M |
| Net Income | -47.08M | -51.04M | -45.57M | -27.88M | -30.50M | -24.44M |
Balance Sheet | ||||||
| Total Assets | 263.43M | 116.48M | 160.26M | 96.72M | 33.03M | 59.03M |
| Cash, Cash Equivalents and Short-Term Investments | 240.13M | 113.12M | 151.25M | 94.90M | 32.34M | 56.73M |
| Total Debt | 1.94M | 78.00K | 78.00K | 65.00K | 211.00K | 348.00K |
| Total Liabilities | 7.28M | 5.10M | 4.45M | 5.65M | 219.98M | 217.29M |
| Stockholders Equity | 256.15M | 111.38M | 155.81M | 91.06M | -186.95M | -158.26M |
Cash Flow | ||||||
| Free Cash Flow | -41.32M | -45.65M | -42.44M | -23.77M | -24.49M | -21.71M |
| Operating Cash Flow | -41.32M | -45.65M | -42.44M | -23.77M | -24.49M | -21.71M |
| Investing Cash Flow | 629.00K | 4.56M | -61.68M | 12.58M | -32.01M | 0.00 |
| Financing Cash Flow | 339.66M | 275.00K | 104.82M | 86.17M | -73.00K | 9.74M |
Sagimet Biosciences, Inc. Class A Technical Analysis
Positive
7.07
Price Trends
7.50
Positive
7.03
Positive
6.64
Positive
Market Momentum
0.67
Negative
77.75
Negative
86.70
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SGMT, the sentiment is Positive. The current price of 7.07 is below the 20-day moving average (MA) of 8.07, below the 50-day MA of 7.50, and above the 200-day MA of 6.64, indicating a bullish trend. The MACD of 0.67 indicates Negative momentum. The RSI at 77.75 is Negative, neither overbought nor oversold. The STOCH value of 86.70 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SGMT.
Sagimet Biosciences, Inc. Class A Risk Analysis
Sagimet Biosciences, Inc. Class A disclosed 78 risk factors in its most recent earnings report. Sagimet Biosciences, Inc. Class A reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Sagimet Biosciences, Inc. Class A Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $567.79M | -8.24 | -31.96% | ― | ― | 30.54% | |
52 Neutral | $406.64M | -2.46 | -64.25% | ― | ― | -29.71% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $290.08M | -1.88 | -57.61% | ― | -94.10% | -122.58% | |
48 Neutral | $116.06M | -2.73 | -38.80% | ― | -100.00% | -392.92% | |
47 Neutral | $175.21M | -4.64 | -74.36% | ― | 35.89% | 58.70% | |
43 Neutral | $441.88M | -1.74 | -128.27% | ― | ― | 41.56% |
* Healthcare Sector Average
SGMT
Sagimet Biosciences, Inc. Class A
10.55
3.00
39.74%
CDXS
Codexis
1.56
-1.44
-48.00%
CABA
Cabaletta Bio
2.75
0.98
55.37%
BDTX
Black Diamond Therapeutics
2.02
-0.73
-26.55%
AVIR
Atea Pharmaceuticals
5.12
1.59
45.04%
TRDA
Entrada Therapeutics Inc
7.46
1.94
35.14%
Sagimet Biosciences, Inc. Class A Corporate Events
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Sagimet Highlights Q2 Results and Dermatology Focus Shift
Positive
Aug 11, 2026
Sagimet Biosciences reported its second-quarter 2026 results on August 11, 2026, highlighting a strategic shift to prioritize dermatology and advance its lead FASN inhibitor denifanstat for moderate to severe acne in the U.S. The company plans a r...
Business Operations and StrategyPrivate Placements and FinancingProduct-Related Announcements
Sagimet updates acne pipeline and funding strategy
Positive
Jul 21, 2026
On July 20, 2026, Sagimet Biosciences updated an investor slide presentation outlining progress across its clinical pipeline and strategic plans. The materials highlight denifanstat’s strong Phase 3 acne data generated by partner Ascletis in...
Executive/Board ChangesShareholder Meetings
Sagimet Biosciences Announces Board Changes and Director Elections
Neutral
Jun 12, 2026
On June 12, 2026, Sagimet Biosciences Inc. announced that board member Tim Walbert resigned from its Board of Directors effective the same day, citing other commitments and noting that his departure did not stem from any disagreement over the comp...
Executive/Board Changes
Sagimet Biosciences Grants New Performance-Based Executive Equity Awards
Positive
Jun 3, 2026
On May 28, 2026, Sagimet Biosciences Inc.’s board and compensation committee granted stock options and performance-based restricted stock units to President and CEO David Happel, CFO Thierry Chauche, and Chief Legal and Administrative Office...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.